Cannabis - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts (2026-2031)

The cannabis market size is valued at USD 39.5 billion in 2025 and is anticipated to grow from USD 45.0 billion in 2026 to USD 86.6 billion by 2031, at a CAGR of 14.0% from 2026 to 2031. This report is Segmented by Product Type (Flower, Pre-Rolls, Concentrates, Edibles, and More), by Usage (Medical, Adult-Use, and Wellness), by Compound (THC-Dominant, CBD-Dominant, and More), by Source (Marijuana and Hemp), by Distribution Channel (Dispensaries, Pharmacies, and More), by Geography (North America, South America, Europe, and More). Forecasts in Value (USD) and Volume (Metric Tons).

Global Cannabis Market Trends and Insights

Expanding Adult-Use and Medical Legalization

The Drug Enforcement Administration's (DEA) rescheduling of medical marijuana from Schedule I to Schedule III, effective April 22, 2026, is projected to result in estimated annual tax relief of USD 1.6 billion to USD 2.2 billion for licensed medical operators, which is anticipated to drive growth and further expansion of adult-use markets. Legal reforms are reshaping the cannabis market by influencing tax policies, licensing incentives, and investor behavior beyond demographic demand. The April 2026 DEA rescheduling decision reduced taxes for state-licensed medical operators while enhancing the federal legitimacy of the United States medical cannabis market, encouraging institutional capital re-engagement. In Europe, Germany’s Cannabis Act (effective April 1, 2024) and France’s March 2025 notification to the European Commission demonstrate progress in regulatory convergence. This convergence underscores the importance of aligning with legal timelines and favoring operators with compliant production and import capabilities and established medical distribution networks. As more countries adopt Germany’s model and related frameworks, companies meeting pharmaceutical standards are poised to gain a competitive edge, driving the market toward greater regional harmonization.

Rising Prescription Use for Chronic Pain and Neurological Symptoms

The cannabis market is gaining momentum as a growing body of medical evidence reduces physician hesitation. A 2025 randomized study in PAIN found that medical cannabis users were 2.6 times more likely to achieve meaningful pain relief than those using prescription medications, alongside a 39.3% reduction in morphine milligram equivalent dosage. Similarly, research in JAMA Internal Medicine linked New York’s medical cannabis program to a 22% reduction in opioid prescribing over 18 months, highlighting economic benefits for payers and health systems. Long-term evidence from a five-year study in Biomedicines showed a decline in Brief Pain Inventory scores for patients with diabetic neuropathy from 9.0 to 2.0, addressing concerns of conservative prescribers. Together, these findings are driving the cannabis market toward formal prescribing pathways, repeat usage, and reimbursement frameworks, reducing its reliance on consumer advocacy.

Banking, Tax, and Interstate Commerce Barriers

The cannabis market in the United States remains inefficient due to incomplete federal reform, even after the April 2026 rescheduling to Schedule III. While medical cannabis operators gained tax relief, the recreational market continues to face inconsistent regulations and restricted access to banking, credit, and insurance services, driving up operational costs. Interstate commerce barriers further intensify these inefficiencies, requiring multi-state operators to replicate production facilities across states rather than centralize operations. These combined challenges hinder the market's ability to achieve scale benefits, underscoring the need for unified federal reforms to unlock its full growth potential.

Other drivers and restraints analyzed in the detailed report include:

• Product Innovation in Edibles, Beverages, and Precision-Dose Formats
• Premiumization Toward High-Potency Flower and Concentrates
• Advertising, Packaging, and Claims Restrictions

For complete list of drivers and restraints, kindly check the Table Of Contents.

Segment Analysis

In 2025, flower accounted for 42.5% of the cannabis market share, maintaining its position as the largest segment and the primary entry format in both medical and adult-use channels due to its familiarity, ease of use, and availability. However, the cannabis market in mature North American states is structurally shifting away from flower, with pre-rolls emerging as a practical alternative that retains much of flower’s appeal while eliminating preparation efforts, particularly for first-time adult-use consumers.

Non-combustible formats such as edibles and capsules remain essential for clinical users prioritizing measured consumption, while topicals and transdermals are gaining traction in medical applications due to fewer regulatory barriers and suitability for specific treatments. Beverages, however, are driving the fastest growth, with a projected CAGR of 14.6% from 2026 to 2031, fueled by advancements in faster-onset technology and their positioning as alcohol alternatives. This shift highlights a growing divide between companies innovating with proprietary formats and those reliant on undifferentiated flower pricing, signaling a long-term transformation in consumer preferences and market dynamics.

Medical cannabis, accounting for 56.8% of the cannabis market share in 2025 by usage, remains the largest segment due to established state programs, physician pathways, and pharmacy-based access models. Its significance lies in stronger repeat behavior, structured referral patterns, and lower customer-acquisition costs than in adult-use retail. Features such as physician oversight, potential reimbursement, and robust patient data collection further solidify its role. Meanwhile, the wellness and nutraceutical segment, driven by CBD-based products, shows potential but faces growth limitations due to regulatory constraints. This underscores the medical segment's critical role in providing stability as adult-use channels expand.

Adult-use cannabis, with a projected CAGR of 14.4% over 2026-2031, is the fastest-growing segment, driven by the transition of illicit purchases into licensed channels. However, much of this growth reflects the formalization of existing consumption rather than new demand. As the initial conversion stabilizes, operators may face challenges in sustaining growth, requiring improved product offerings, retail execution, and disciplined capital allocation. Despite the rapid growth of adult-use, the cannabis market's reliance on the medical segment persists, as its structured and stable economics provide a foundation that open retail competition alone cannot match. Together, these dynamics highlight the interdependence of medical stability and adult-use growth in shaping the market's future.

Complete Report Scope:

• By Product Type
  • Flower
  • Pre-Rolls
  • Concentrates
  • Edibles
  • Beverages
  • Topicals and Transdermals
  • Tinctures and Sublinguals
  • Capsules and Softgels
• By Usage
  • Medical
  • Adult-Use / Recreational
  • Wellness and Nutraceutical
• By Compound
  • THC-Dominant
  • CBD-Dominant
  • Balanced THC/CBD
  • Minor Cannabinoids
• By Source
  • Marijuana
  • Hemp
• By Distribution Channel
  • Dispensaries
  • Pharmacies
  • Online Direct-to-Consumer
  • Delivery Services
  • Mass-Market Retail
• By Geography
  • North America
    • United States
    • Canada
    • Mexico
    • Rest of North America
  • South America
    • Brazil
    • Colombia
    • Argentina
    • Rest of South America
  • Europe
    • Germany
    • United Kingdom
    • France
    • Italy
    • Netherlands
    • Spain
    • Russia
    • Rest of Europe
  • Asia-Pacific
    • Australia
    • Thailand
    • Japan
    • South Korea
    • New Zealand
    • Rest of Asia-Pacific
  • Middle East
    • Israel
    • Turkey
    • United Arab Emirates
    • Rest of Middle East
  • Africa
    • South Africa
    • Lesotho
    • Morocco
    • Rest of Africa

Geography Analysis

In 2025, North America dominated the cannabis market with a 73.0% share, driven by the United States' extensive multi-state operator base and Canada's mature retail system. However, growth in the region is anticipated to slow as legalization-led opportunities have largely been realized. Future expansion will depend on federal reforms, interstate commerce regulations, and consolidation strategies. In contrast, Europe is emerging as a key growth region, with Germany advancing medical access and France signaling broader policy changes, indicating a shift towards a more integrated market.

The Asia-Pacific region, with a projected CAGR of 14.8% from 2026 to 2031, is the fastest-growing segment, though growth is concentrated in regulated medical systems. Australia plays a pivotal role, supported by updates to the Authorized Prescriber framework in December 2025 that bolster the prescription channel. Significant demand is evident, with Australians spending AUD 400 million (USD 260 million) on medicinal cannabis in the first half of 2024, despite the market's reliance on imports. Similarly, South America, with a projected CAGR of 13.6% over 2026-2031, is building its regulated supply framework, led by Colombia and Brazil. Colombia's recognition of cannabis flower as a medicinal product and Brazil's regulatory advancements in 2026 are anticipated to strengthen compliance and production capabilities, driving regional growth.

In the Middle East, Israel remains the primary driver due to its regulated medical framework, though reliance on imports makes the market sensitive to trade policies. Africa's growth is led by South Africa, Morocco, and Lesotho, leveraging cultivation potential and export-oriented medical cannabis. Morocco and Lesotho are particularly significant for integrating into regulated export supply chains, aligning with global trends of expanding medical access and stricter quality standards. Together, these regional developments highlight a global cannabis market transitioning from initial legalization phases to a more structured and regulated growth trajectory.

List of Companies Covered in this Report:

• Curaleaf Holdings, Inc.
• Trulieve Cannabis Corp.
• Green Thumb Industries Inc.
• Verano Holdings Corp.
• Cresco Labs Inc.
• Ascend Wellness Holdings, Inc.
• High Tide Inc.
• SNDL Inc.
• Jazz Pharmaceuticals plc
• Jushi Holdings Inc.
• TerrAscend Corp.
• Aurora Cannabis Inc.
• Tilray Brands, Inc.
• Organigram Global Inc.
• Cronos Group Inc.

Additional Benefits:

• The market estimate (ME) sheet in Excel format
• 3 months of analyst support